A carregar...
Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide is non‐inferior to once‐daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26‐week randomized phase III study
AIMS: To examine the efficacy and safety of once‐weekly dulaglutide monotherapy (0.75 mg) compared with placebo and once‐daily liraglutide (0.9 mg) in Japanese patients with type 2 diabetes. METHODS: This was a phase III, 52‐week (26‐week primary endpoint), randomized, double‐blind, placebo‐controll...
Na minha lista:
| Publicado no: | Diabetes Obes Metab |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Blackwell Publishing Ltd
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5042083/ https://ncbi.nlm.nih.gov/pubmed/26179187 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.12534 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|